Sign in
4

Changes in Ownership

Sionna Therapeutics, Inc. Filed Acc 0001704336-25-000006

President & CEO sold 25,200 shares at an average $31.28 ($788,153)

  • President & CEO acquired 25,200 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Cloonan Michael · President & CEO

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2025-10-15 Exercise or conversion : show line 1 in the form 10b5-1 +14,775 $6.11 $90,275 562,118 D
2025-10-15 Sale : show line 2 in the form 10b5-1 −14,775 $31.11 $459,662 547,343 D
2025-10-16 Exercise or conversion : show line 3 in the form 10b5-1 +10,225 $6.11 $62,475 557,568 D
2025-10-16 Sale : show line 4 in the form 10b5-1 −10,225 $31.46 $321,691 547,343 D
2025-10-16 Exercise or conversion : show line 5 in the form 10b5-1 +200 $6.11 $1,222 547,543 D
2025-10-16 Sale : show line 6 in the form 10b5-1 −200 $34.00 $6,800 547,343 D
Open-market sales · 25,200 sh · avg $31.28 · $788,153

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2025-10-15 Exercise or conversion : show line 7 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −14,775 163,367 D
2025-10-16 Exercise or conversion : show line 8 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −10,225 153,142 D
2025-10-16 Exercise or conversion : show line 9 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −200 152,942 D
Loading xslF345X05/edgardoc.xml…